| Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated … DE Fouts, R Pieper, S Szpakowski, H Pohl, S Knoblach, MJ Suh, ... Journal of translational medicine 10, 1-17, 2012 | 463 | 2012 |
| Next generation sequencing to define prokaryotic and fungal diversity in the bovine rumen DE Fouts, S Szpakowski, J Purushe, M Torralba, RC Waterman, ... PloS one 7 (11), e48289, 2012 | 336 | 2012 |
| PD-1 blockade in anaplastic thyroid carcinoma J Capdevila, LJ Wirth, T Ernst, SP Aix, CC Lin, R Ramlau, MO Butler, ... Journal of Clinical Oncology 38 (23), 2620, 2020 | 221 | 2020 |
| Loss of epigenetic silencing in tumors preferentially affects primate-specific retroelements S Szpakowski, X Sun, JM Lage, A Dyer, J Rubinstein, D Kowalski, ... Gene 448 (2), 151-167, 2009 | 139 | 2009 |
| MicroRNA signatures differentiate melanoma subtypes E Chan, R Patel, S Nallur, E Ratner, A Bacchiocchi, K Hoyt, S Szpakowski, ... Cell cycle 10 (11), 1845-1852, 2011 | 117 | 2011 |
| Phosphoproteomic screen identifies potential therapeutic targets in melanoma K Tworkoski, G Singhal, S Szpakowski, CI Zito, A Bacchiocchi, ... Molecular cancer research 9 (6), 801-812, 2011 | 110 | 2011 |
| Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) U Borate, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ... Blood 134, 570, 2019 | 80 | 2019 |
| Phase 2 Study of the HSP-90 Inhibitor AUY922 in previously treated and molecularly defined patients with advanced non–small cell lung cancer E Felip, F Barlesi, B Besse, Q Chu, L Gandhi, SW Kim, E Carcereny, ... Journal of Thoracic Oncology 13 (4), 576-584, 2018 | 79 | 2018 |
| Genomic profiling of metastatic uveal melanoma and clinical results of a phase I study of the protein kinase C inhibitor AEB071 S Piperno-Neumann, J Larkin, RD Carvajal, JJ Luke, GK Schwartz, ... Molecular cancer therapeutics 19 (4), 1031-1039, 2020 | 51 | 2020 |
| Using Bayesian modelling to investigate factors governing antibiotic-induced Candida albicans colonization of the GI tract J Shankar, NV Solis, S Mounaud, S Szpakowski, H Liu, L Losada, ... Scientific reports 5 (1), 8131, 2015 | 41 | 2015 |
| Phase II, randomized study of Spartalizumab (PDR001), an anti–PD-1 antibody, versus chemotherapy in patients with recurrent/metastatic nasopharyngeal cancer C Even, HM Wang, SH Li, RKC Ngan, A Dechaphunkul, L Zhang, CJ Yen, ... Clinical cancer research 27 (23), 6413-6423, 2021 | 37 | 2021 |
| Microbiome in human health and disease R Madupu, S Szpakowski, KE Nelson Science progress 96 (2), 153-170, 2013 | 29 | 2013 |
| A systematic evaluation of high-dimensional, ensemble-based regression for exploring large model spaces in microbiome analyses J Shankar, S Szpakowski, NV Solis, S Mounaud, H Liu, L Losada, ... BMC bioinformatics 16, 1-18, 2015 | 19 | 2015 |
| Sequence-specific biosensors report drug-induced changes in epigenetic silencing in living cells X Huang, R Narayanaswamy, K Fenn, S Szpakowski, C Sasaki, J Costa, ... DNA and cell biology 31 (S1), S-2-S-10, 2012 | 19 | 2012 |
| Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study SA Piha-Paul, MH Taylor, D Spitz, L Schwartzberg, JT Beck, TM Bauer, ... Oncotarget 10 (60), 6526, 2019 | 18 | 2019 |
| Abstract CT150: Phase II study of spartalizumab (PDR001) vs chemotherapy (CT) in patients with recurrent/metastatic nasopharyngeal cancer (NPC) DWT Lim, HM Wang, SH Li, R Ngan, A Dechaphunkul, L Zhang, CJ Yen, ... Cancer Research 79 (13_Supplement), CT150-CT150, 2019 | 18 | 2019 |
| Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1. DSW Tan, DW Kim, M Thomas, S Pantano, Y Wang, SL Szpakowski, ... Journal of Clinical Oncology 34 (15_suppl), 9064-9064, 2016 | 17 | 2016 |
| AML-190: anti-TIM-3 antibody MBG453 in combination with hypomethylating agents (HMAs) in patients with high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia: a … A Brunner, U Borate, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ... Clinical Lymphoma Myeloma and Leukemia 20, S188-S189, 2020 | 15 | 2020 |
| Abstract CT034: Phase I study of WNT974+ spartalizumab in patients (pts) with advanced solid tumors F Janku, F de Vos, M de Miguel, P Forde, A Ribas, M Nagasaka, G Argiles, ... Cancer Research 80 (16_Supplement), CT034-CT034, 2020 | 15 | 2020 |
| Methylation biomarkers and methods of use PM Lizardi, S Szpakowski, M Chen, J Costa, H Zhao US Patent App. 13/390,669, 2012 | 12 | 2012 |
